EichorEICHOR
Condition: Gastro Esophageal Junctional Cancer Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Gastro Esophageal Junctional Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Spanish Registry of Esophagogastric Cancer
Phase N/A · 38 location(s) · Fundación Sociedad Española de Oncologia Médica · NCT04958720A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 25 location(s) · AstraZeneca · NCT06005493Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT04592211Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Phase 2/Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05427383A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable
Phase 1 · 4 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07059299Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NA · 1 location(s) · The Second Hospital of Shandong University · NCT04688801mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 793 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gas
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT04850729Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Pat
NA · 1 location(s) · Masaryk Memorial Cancer Institute · NCT07671625Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal
Phase 2 · 1 location(s) · Sanofi · NCT07692204Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NA · 363 location(s) · Alliance for Clinical Trials in Oncology · NCT07283939ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
EARLY_Phase 1 · 1 location(s) · University of California, Irvine · NCT06824363Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Phase 3 · 15 location(s) · SOFIE · NCT07217704A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
NA · 1 location(s) · Nurettin Şahin · NCT07482566A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 54 location(s) · Merus B.V. · NCT03526835Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 · 17 location(s) · SystImmune Inc. · NCT06293898Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Phase N/A · 1 location(s) · Stanford University · NCT01048281A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction A
Phase 1 · 3 location(s) · Dong-A ST Co., Ltd. · NCT07481357Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT04221893DBC-664 in Adult Patients With Solid Tumors
Phase 1 · 3 location(s) · Duboce Biopharmaceuticals, Inc. · NCT07705035
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.